Advances in Haemophilia Treatment:New Hope for Patients

Haemophilia is a genetic disorder that affects the blood’s ability to clot, leading to prolonged bleeding. There are two main types of haemophilia: Haemophilia A (deficiency in clotting factor VIII) and Haemophilia B (deficiency in clotting factor IX).

Causes and Symptoms:

Haemophilia is caused by a mutation in the gene that codes for clotting factor VIII or IX, leading to a deficiency or malfunction of these proteins.

Symptoms include:

– Prolonged bleeding after injury or surgery

– Frequent nosebleeds

– Joint pain and swelling due to bleeding into joints

– Muscle weakness

Current Treatments–

• Replacement Therapy: Replacement therapy is a treatment approach for haemophilia that involves infusing the missing clotting factor into the blood to help it clot properly. This therapy has been a cornerstone of haemophilia treatment for decades.

Types of Replacement Therapy

–On-demand treatment: Infusing clotting factor as needed to treat acute bleeding episodes.

–Prophylactic treatment: Regular infusions of clotting factor to prevent bleeding episodes and joint damage.

• Desmopressin: Desmopressin is a synthetic hormone that can be used to treat mild to moderate haemophilia A. It works by stimulating the release of factor VIII from storage sites in the body.

How Desmopressin Works

– Stimulates factor VIII release: Desmopressin increases the levels of factor VIII in the blood, helping to control bleeding.

– Temporary solution: Desmopressin is typically used for minor bleeding episodes or as a preventive measure before minor surgery.

Haemophilia is a complex genetic disorder that requires comprehensive treatment and care. While current treatments have improved outcomes, emerging therapies offer promise for further advancements. Continued research and innovation will be crucial in improving treatment options and outcomes for individuals with haemophilia.